



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449b, TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 27, 2004

(use as many sheets as necessary)

Complete if Known

Application Number	10/081,147
Filing Date	02/25/2002
First Named Inventor	Peng Cho Tang
Group Art Unit	1626
Examiner Name	Sonya N. Wright
Attorney Docket Number	034536-0400

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SNW	A1	4,002,749		Rovnyak	01/11/1977	
SNW	A2	4,966,849		Vallee et al.	10/30/1990	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner
Signature

Sonya Wright

Date
Considered

4-7-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

	AU	94-10202	05-11-94	WO-PCT (Johnston et al.)				
<i>QNW</i>	AV	94-14808	07-07-94	WO-PCT (Buzzetti et al.)				
	AW	95-24190	09-14-95	WO-PCT (Chen et al.)				
	AX	96-00226	01-04-96	WO-PCT (Buzzetti et al.)				
	AY	96-16964	06-06-96	WO-PCT (Buzzetti et al.)				
<i>QNW</i>	AZ	96-40116	12-19-96	WO-PCT (Tang et al.)				
<i>QNW</i>	BA	98-07695	02-26-98	WO-PCT (Tang et al.)				
	BB	98-07835	02-26-98	WO-PCT (Mohammadi)				
	BC	98-45708	10-16-98	WO-PCT (Clary)				
	BD	98-50350	11-12-98	WO-PCT (Tang et al.)				
	BE	98-56376	12-17-98	WO-PCT (Tang et al.)				
	BF	99-10325	03-04-99	WO-PCT (McNutt et al.)				
	BG	0 252 731 A1	01-13-88	EP(Howard)				
<i>QNW</i>	BH	0 566 226 A1	10-20-93	EP (Barker)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>QNW</i>	BI	Akbasak and Sunar-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
	BJ	Andreani et al., "Synthesis and potential <u>coanthracetylinic</u> activity of substituted 3-(5-imidazo[2,1-b]thiazolymethylene) 2 indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924(1997)
	BK	Andreani et al., "In vivo cardiotoxic activity of pyridylmethylene 2-indolinones" <u>Arzneimittel-Forschung Drug Research</u> 48(11): 727-729 (1998)
<i>QNW</i>	BL	Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)
	BM	Arvidsson et al., "Try-716 in the Platelet-Derived-Growth-Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)
	BN	Baserga, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994)
	BO	Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)
	BP	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)
	BQ	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)
<i>QNW</i>	BR	Bonner et al., "Structure and Biological Activity of Human Homologs of the raf-mil Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985)

EXAMINER:

Sonya Wright

DATE CONSIDERED:

10-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant